secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001104659-25-010148
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics updates on GT-02287 Phase 1b trial for Parkinson's disease
----------------------------------------------------------------------------

- Phase 1b trial of GT-02287 approved; dosing imminent in Australia, enrolling 15-20 patients with GBA1 or idiopathic PD.
- Prior healthy volunteer study showed 53% increase in GCase activity and confirmed safety/tolerability.
- Cash of $12M as of September 30, 2024, expected to fund operations through interim analysis in 2Q 2025.
- FDA pre-IND meeting found no significant regulatory hurdles; IND submission on track for Phase 2 planning in 2H 2025.
- Promotion of Gianluca Fuggetta to SVP Finance; company exploring licensing partners and financing options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/0001104659-25-010148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/tm255679d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-010148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer